January 08, 2026
2 min read
Key takeaways:
- CAM360 AmnioGraft led to rapid decreases in corneal staining scores in the days after treatment.
- At least one symptom of ocular surface disease was resolved in 65% of treated eyes.
Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable cryopreserved amniotic membrane, according to a study published in Clinical Optometry.
The retrospective study explored the short- and long-term clinical outcomes of CAM360 AmnioGraft (BioTissue) for the treatment of dry eye disease and other ocular surface diseases. CAM360 AmnioGraft is intended to be more useful for patients with mild to moderate ocular surface disease than the company’s Prokera, which is often used in moderate to severe cases.
Sean P. Cushman
“The key differences between the new shelf-stable cryopreserved [amniotic membrane] and Prokera are that it does not have a ring to hold the [cryopreserved amniotic membrane] in place and undergoes additional terminal sterilization process, which allows it to be stored at room temperature,” study author Sean P. Cushman, OD, FAAO, of the Eye Institute of Utah, wrote. “Potential benefits of such treatment include short duration of treatment (eg, 2-3 days), improved patient discomfort, and both rapid and durable improvement in signs and symptoms.”
Cushman analyzed data on ocular surface disease treated with CAM360 AmnioGraft at his center between January 2024 and March 2025. The study included 29 eyes of 20 patients, 14 with dry eye disease, five with neurotrophic keratopathy and 10 with superficial punctate keratitis.
CAM360 AmnioGraft was placed onto either a 72-hour dissolvable collagen shield or a bandage contact lens. Treated eyes were taped partially shut for 2 to 3 days, during which patients were instructed to continue using topical medications.
Clinical outcomes were assessed 1 week (± 5 days) after treatment and between 12 and 24 weeks after treatment. The primary outcome was the 1-week change in corneal surface integrity, measured by fluorescein staining on a 4-point scale, with 4 points indicating severe punctate keratitis.
At the first follow-up visit, an average of 3.9 ± 2.9 days after treatment, 84.6% of eyes had improved corneal staining. The average staining score improved from 2.26 ± 1.07 at baseline to 1 ± 0.91 at the first visit (P < .001).
The average staining score increased to 1.55 ± 1.13 at the final follow-up visit, an average of 16 ± 2.8 weeks after treatment, but remained significantly improved from baseline (P = .014). Trace staining remained in three eyes, whereas five eyes had complete resolution.
“We observed rapid corneal healing with a shelf-stable cryopreserved amniotic membrane that was stored at room temperature,” Cushman said in a statement to Healio. “This breakthrough overcomes the cold storage limitations of traditional membranes, making advanced ocular surface therapy more accessible and practical.”
Symptomatic improvement, defined as the resolution of at least one symptom that existed before treatment, occurred in 65% of eyes. Complications consisted of three cases of irritation noted during the first follow-up visit only: two were attributed to the collagen shield, and one on the outer lid was attributed to adhesive tape.
Rodger Kennedy
“Seeing patients experience fast relief from symptoms and measurable corneal healing within just a few days is a major step forward in making effective ocular surface treatment more accessible and convenient, ultimately helping more patients receive timely, effective care,” Rodger Kennedy, senior director of marketing, BioTissue Ocular, told Healio in a statement.
For more information:
Sean P. Cushman, OD, FAAO, can be reached at scushman@theeyeinstitute.com.
Sources/Disclosures
Source:
Cushman S. Clin Optom. 2025;doi:10.2147/OPTO.S563708.
Disclosures:
Cushman reports being a speaker for Bausch + Lomb outside this study. Kennedy reports being an employee of BioTissue Ocular. The Eye Institute of Utah received an educational grant from BioTissue Holdings for this study.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
